Avalo Therapeutics, Inc.
AVTX
$19.94
-$0.31-1.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -12.07% | -6.29% | |||
| Gross Profit | 12.66% | 6.29% | |||
| SG&A Expenses | 17.16% | 6.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.14% | -0.61% | |||
| Operating Income | -2.83% | 0.61% | |||
| Income Before Tax | 55.61% | -47.54% | |||
| Income Tax Expenses | 1,081.82% | -31.25% | |||
| Earnings from Continuing Operations | 55.20% | -47.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 55.20% | -47.48% | |||
| EBIT | -2.83% | 0.61% | |||
| EBITDA | -3.07% | 0.22% | |||
| EPS Basic | 65.60% | -14.08% | |||
| Normalized Basic EPS | 65.91% | -14.13% | |||
| EPS Diluted | 65.53% | -14.06% | |||
| Normalized Diluted EPS | 65.91% | -14.13% | |||
| Average Basic Shares Outstanding | 30.22% | 29.28% | |||
| Average Diluted Shares Outstanding | 30.22% | 29.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||